BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28332354)

  • 1. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
    Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
    Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
    N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
    Qiang YW; Chen Y; Stephens O; Brown N; Chen B; Epstein J; Barlogie B; Shaughnessy JD
    Blood; 2008 Jul; 112(1):196-207. PubMed ID: 18305214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
    Edwards CM; Edwards JR; Lwin ST; Esparza J; Oyajobi BO; McCluskey B; Munoz S; Grubbs B; Mundy GR
    Blood; 2008 Mar; 111(5):2833-42. PubMed ID: 18094333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.
    Morvan F; Boulukos K; Clément-Lacroix P; Roman Roman S; Suc-Royer I; Vayssière B; Ammann P; Martin P; Pinho S; Pognonec P; Mollat P; Niehrs C; Baron R; Rawadi G
    J Bone Miner Res; 2006 Jun; 21(6):934-45. PubMed ID: 16753024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing Roles of Wnt Inhibitors IGFBP-4 and Dkk1 in Cardiac Ischemia by Differential Targeting of LRP5/6 and β-catenin.
    Wo D; Peng J; Ren DN; Qiu L; Chen J; Zhu Y; Yan Y; Yan H; Wu J; Ma E; Zhong TP; Chen Y; Liu Z; Liu S; Ao L; Liu Z; Jiang C; Peng J; Zou Y; Qian Q; Zhu W
    Circulation; 2016 Dec; 134(24):1991-2007. PubMed ID: 27803037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
    Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ
    Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
    Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
    Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss.
    Wang FS; Ko JY; Yeh DW; Ke HC; Wu HL
    Endocrinology; 2008 Apr; 149(4):1793-801. PubMed ID: 18174290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
    Feng Y; Zhang Y; Wei X; Zhang Q
    Cancer Biomark; 2019; 24(2):195-201. PubMed ID: 30614800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.
    Faraahi Z; Baud'huin M; Croucher PI; Eaton C; Lawson MA
    Bone; 2019 May; 122():82-92. PubMed ID: 30776499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
    Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
    J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
    Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
    PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
    Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
    Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.